Key Takeaway: A recent pilot study investigated the effects of CT1812 on synaptic activity in patients with mild to moderate Alzheimer's disease. Conducted by Vijverberg et al., the research aims to explore the treatment's potential benefits. The findings could provide insights into new therapeutic strategies for managing Alzheimer's.
Price reaction · baseline $0.645 (2024-08-06 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
-9.8%
day 1
-9.3%
day 3 · peak
-11.8%
Market Sentiment Analysis
POSITIVE FACTORS
The study focuses on a novel treatment for Alzheimer's disease.
CT1812 shows potential for enhancing synaptic activity.
The research contributes to understanding Alzheimer's treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Vijverberg E, de Haan W, Scheijbeler E. et al. A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer’s Disease . J Prev Alzheimers Dis (2024).
Frequently Asked Questions
What is the focus of the CT1812 study?
The study focuses on the effect of CT1812 treatment on synaptic activity in Alzheimer's patients.
Who conducted the CT1812 pilot study?
The pilot study was conducted by researchers Vijverberg, de Haan, and Scheijbeler.
What type of patients were included in the study?
Patients with mild to moderate Alzheimer's disease were included in the study.
What journal published the CT1812 study?
The study was published in the Journal of Prevention of Alzheimer's Disease.